

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Maurer et al.	DOCKET NO.:	112843-006
SERIAL NO:	09/674,738	ART UNIT:	Unknown
FILED:	October 31, 2000	EXAMINER:	Unknown
INVENTION:	"USE OF BROMELAIN PROTEASES FOR INHIBITING BLOOD COAGULATION"		

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Sir:


This Response is submitted in response to the Notification of Defective Response ("Notice") mailed on August 24, 2001. In the Notice, the Patent Office alleges that the response to the Notice of Missing Parts mailed on May 21, 2001 was not complete. More specifically, the Patent Office alleges that the Sequence Listing and related documents have not been filed in response to the Notice of Missing Parts.

During a telephone conference with the Patent Office on September 20, 2001 between Ms. Karen Williams of the Patent Office and Mr. Thomas C. Basso, on behalf of Applicants, the Patent Office acknowledged receipt of all documents relating to the filing of the Sequence Listing except for a disk copy regarding same. In response, Applicants respectfully reminded the Patent Office the Sequence Listing was sent via EFS on August 21, 2001 along with the other documents in addition to an EFS filing receipt from the Patent Office acknowledging same.

Based on these discussions, the Patent Office acknowledged receipt of same and informed Applicants that they have been responsive to the Notice of Missing Parts unless further notified. Therefore, Applicants respectfully submit that they have fully responded to the Notice of Missing Parts and are responsive to this Notice based on the discussions with the Patent Office as summarized above.

Accordingly, Applicants respectfully request an early and favorable examination of the present application.

Respectfully submitted,



(Reg. No. 30,142)

Robert M. Barrett
BELL, BOYD & LLOYD LLC
P.O. Box 1135
Chicago, Illinois 60690-1135
Tel: (312) 807-4204
ATTORNEY FOR APPLICANT

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Maurer et al.

Docket No.

112843-006

Serial No.

09/674,738

Filing Date

October 31, 2000

Examiner

Group Art Unit

Invention: **USE OF BROMELAIN PROTEASES FOR INHIBITING BLOOD COAGULATION**

I hereby certify that the following correspondence:

Transmittal letter to the United States Designated/Elected Office in duplicate, Form PCT/DO/EO/916, Form PCT/DO/EO/920, Response to Notification of Defective Response, postcard

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on

September 24, 2001*(Date)*
Robert Buccieri*(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)*

EL647240416US

*("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing.**



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/674738	MAURER	R 112843-006
INTERNATIONAL APPLICATION NO.		

ROBERT M BARRETT
BELL BOYD & LLOYD
P O BOX 1135
CHICAGO, IL 60690 1135

PCT/EP98/04406

I.A. FILING DATE	PRIORITY DATE
15 JUL 98	

DUE: 9-24-01
DATE MAILED: 24 AUG 2001

NOTIFICATION OF A DEFECTIVE RESPONSE

1. ☐ The request for an extension of time (37 CFR 1.136(a)) filed _____ is defective because the required fee is missing/insufficient. Extension of time fees are listed at 37 CFR 1.17(a)(1)-(a)(5).
2. ☐ Applicant's response filed _____ was received in the Office after the expiration of the period for response set in the Office notification mailed _____. This application will become abandoned unless applicant obtains an extension of time to reply to the last Office notification under 37 CFR 1.136(a).
3. ☒ Applicant's response filed 25 JUL 01 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS (Form PCT/DO/EO/905) mailed 21 MAY 01 have not been completed.

- ☐ Translation of the international application into English.
☐ which is defective for the reasons indicated on the attached Notice of Defective Translation.
- ☐ Processing fee (37 CFR 1.492(f)).
- ☐ Oath or Declaration of inventor(s).
☐ not in compliance with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.
- ☐ Surcharge (37 CFR 1.492(e)).
- ☒ Sequence Listing.
☒ not in compliance with 37 CFR 1.821-1.825 for the reasons indicated on the attached PCT/DO/EO/920.
- ☐ Additional claim fees.
- PCT OFFICE RECEIVED DECLARATION WITH SURCHARGE DATED 25 JUL 01. PCT OFFICE RECEIVED INFORMATION DISCLOSURE STATEMENT DATED 02 JAN 01.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements (Form DO/EO/905), whichever is the longer. No extension of this time limit may be granted under 37 C.F.R. § 1.136, but the period for response set in the Notification of Missing Requirements (Form DO/EO/905) may be extended under 37 C.F.R. § 1.136(a).

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

Enclosed: ☐ PCT/DO/EO/917 ☐ Notice of Defective Translation
☒ PCT/DO/EO/920

RECEIVED
BELL, BOYD & LLOYD
INTELLECTUAL PROPERTY DOCKET

FORM PCT/DO/EO/916 (March 2001)

AUG 27 2001 TK

Karen Williams

Telephone: 703-305-3688

ATTY: RMB
DOCKET #: 112843-006



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/674738	MAURER	R 112843-006
INTERNATIONAL APPLICATION NO.		

ROBERT M BARRETT
BELL BOYD & LLOYD
P O BOX 1135
CHICAGO, IL 60690 1135

PCT/EP98/04406

I.A. FILING DATE

PRIORITY DATE

15 JUL 98

DATE MAILED:

24 AUG 2001

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- ☐ This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- ☒ A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- ☐ A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☒ Other: SEQUENCE LISTING HAS NOT BEEN TRANSLATED

APPLICANT MUST PROVIDE:

- ☒ An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- ☒ An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
CALL:

(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.

Karen Williams *KW*

Telephone: 703-305-3688

FORM PTO-1390 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

112843-006

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/674,738

INTERNATIONAL APPLICATION NO.
PCT/EP98/04406

INTERNATIONAL FILING DATE
July 15, 1998

PRIORITY DATE CLAIMED

TITLE OF INVENTION

USE OF BROMELAIN PROTEASES FOR INHIBITING BLOOD COAGULATION

APPLICANT(S) FOR DO/EO/US

Maurer et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☐ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

Response to Notification of Defective Response
Copy of Form PCT/DO/EO/916 (March 2001)
Form PCT/DO/EO/920 (March 2001)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.492(a)(1)) 09/674,738	INTERNATIONAL APPLICATION NO. PCT/EP98/04406	ATTORNEY'S DOCKET NUMBER 112843-006
--	--	---

21. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **\$1,000.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **\$860.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$710.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$690.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) **\$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	- 20 =	0	x \$18.00		\$0.00
Independent claims	- 3 =	0	x \$80.00		\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL OF ABOVE CALCULATIONS =					\$0.00
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable) <input type="checkbox"/>					\$0.00
SUBTOTAL =					\$0.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).					\$0.00
TOTAL NATIONAL FEE =					\$0.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL FEES ENCLOSED =					\$0.00
					Amount to be:
					refunded
					\$
					charged
					\$

CALCULATIONS PTO USE ONLY

☐ A check in the amount of _____ to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **02-1818** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Robert M. Barrett (Reg. No. 30,142)
 Bell, Boyd & Lloyd LLC
 P.O. Box 1135
 Chicago, Illinois 60690

 SIGNATURE
Robert M. Barrett

 NAME
30,142)

 REGISTRATION NUMBER
September 24, 2001

 DATE